In yesterday’s Wall Street session, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) shares traded at $18.58, down -0.69% from the previous session.
As we calculate the median target price by taking the range between a high of $19.00 and a low of $12.00, we find $19.00. Given the previous closing price of $18.71, this indicates a potential upside of 1.55 percent. ICPT stock price is now 70.59% away from the 50-day moving average and 32.33% away from the 200-day moving average. The market capitalization of the company currently stands at $776.27M.
Brokers who have rated the stock have averaged $18.30 as their price target over the next twelve months.
With the price target enhanced from $8 to $19, H.C. Wainwright Upgraded its rating from Sell to Buy for Intercept Pharmaceuticals Inc (NASDAQ: ICPT).
Insiders disposed of 23,416 shares of company stock worth roughly $0.44 million over the past 1 year. A total of 19.18% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ICPT stock. A new stake in Intercept Pharmaceuticals Inc shares was purchased by DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) during the first quarter worth $38,607,000. CALIGAN PARTNERS LP invested $24,033,000 in shares of ICPT during the first quarter. In the first quarter, DG CAPITAL MANAGEMENT, LLC acquired a new stake in Intercept Pharmaceuticals Inc valued at approximately $16,653,000. GREAT POINT PARTNERS I LP acquired a new stake in ICPT for approximately $11,173,000. ALTIUM CAPITAL MANAGEMENT LP purchased a new stake in ICPT valued at around $6,001,000 in the second quarter. In total, there are 219 active investors with 77.50% ownership of the company’s stock.
Wednesday morning saw Intercept Pharmaceuticals Inc (NASDAQ: ICPT) opened at $18.39. During the past 12 months, Intercept Pharmaceuticals Inc has had a low of $8.82 and a high of $21.86. As of last week, the company has a debt-to-equity ratio of 4.94, a current ratio of 2.52, and a quick ratio of 2.52. The fifty day moving average price for ICPT is $11.04 and a two-hundred day moving average price translates $14.06 for the stock.
The latest earnings results from Intercept Pharmaceuticals Inc (NASDAQ: ICPT) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.14, beating analysts’ expectations of -$0.51 by 0.37. This compares to $0.43 EPS in the same period last year. The company reported revenue of $83.72 million for the quarter, compared to $71.76 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 16.67 percent. For the current quarter, analysts expect ICPT to generate $88.51M in revenue.
Intercept Pharmaceuticals Inc(ICPT) Company Profile
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey.
